Related Experiment Video

Updated: Dec 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature

Chakrabhavi Dhananjaya Mohan1, Shobith Rangappa2, Habbanakuppe D Preetham3

  • 1Department of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysore 570006, India.

Seminars in Cancer Biology
|April 24, 2020
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) is crucial in cancer development and progression. Inhibiting STAT3 signaling shows promise for effective cancer therapy by suppressing tumor growth.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Oncology

Background:

  • Signal transducer and activator of transcription (STAT) proteins are key regulators of gene expression.
  • STAT3 is frequently implicated in human malignancies, promoting cancer cell proliferation, survival, and metastasis.
  • Constitutive STAT3 activation is observed across various cancer types, correlating with poor prognosis.

Purpose of the Study:

  • To provide a comprehensive review of STAT3 signaling in cancer.
  • To explore mechanisms of STAT3 activation, negative modulation, and its role in oncogenesis.
  • To discuss the therapeutic potential of inhibiting STAT3 signaling, including natural compounds.

Main Methods:

  • Literature review of STAT3 signaling pathways.
  • Analysis of STAT3's role in various cancers.
  • Overview of negative regulators and miRNA interplay in STAT3 signaling.
  • Examination of natural compounds as STAT3 inhibitors.

Main Results:

  • STAT3 upregulates genes involved in cell proliferation, anti-apoptosis, angiogenesis, and immune evasion.
  • STAT3 is constitutively activated in numerous solid and hematological tumors.
  • Inhibition of STAT3 signaling effectively suppresses tumor progression in preclinical models.

Conclusions:

  • STAT3 is a critical oncogenic driver and a promising therapeutic target in cancer.
  • Targeting STAT3 signaling, potentially with natural compounds, offers a viable strategy for cancer treatment.
  • Understanding STAT3's complex signaling network is essential for developing effective therapies.
Keywords:
JAK-STAT signalingNatural compoundsTranscription factorsTumorigenesis

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K